By CH Unnikrsihnan Drug maker and researcher Glenmark Pharmaceuticals Ltd's new biological drug candidate Bi-Specific ...

This week's report explores the pharmaceutical industry’s evolution toward resilient, scalable systems that prioritize ...

Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of ...

Key market opportunities in the antibody optimization service industry include addressing rising chronic and complex diseases ...

ITI-5000 utilizes nucleic acid vaccine constructs engineered to preferentially deliver tumor-associated antigens (TAAs) to the MHC II compartment via LAMP-1, potentially enhancing antigen presentation ...

Artificial intelligence (AI) and “protein language” models can speed the design of monoclonal antibodies that prevent or reduce the severity of potentially life-threatening viral infections, according ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the ...

A look at the clinical progress of anti-Aβ monoclonal antibodies and how precision delivery is shaping the next generation of ...

HONG KONG, Jan. 19, 2026 /PRNewswire/ -- (9926.HK) announced that its supplemental New Drug Application (sNDA) for gumokimab (AK111), a novel humanized anti-IL-17A monoclonal antibody for the treatmen ...

A multidisciplinary team has uncovered a key mechanism that allows the human bacterium Mycoplasma pneumoniae—responsible for ...

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by ...

Monoclonal antibodies (mAbs) aid the body against autoimmune diseases and cancer, among other things. Patients have to pick ...